About the Authors
- Ilya Kovalenko
-
Affiliations Drug Discovery, Therapeutic Research Groups / Onc II, Bayer Pharma AG, Berlin, Germany, Department of Bioanalytics, Institute of Biotechnology, Technische Universität Berlin, Berlin, Germany
- Andrea Glasauer
-
Affiliation Drug Discovery, Therapeutic Research Groups / Onc II, Bayer Pharma AG, Berlin, Germany
- Laura Schöckel
-
Affiliation Drug Discovery, Therapeutic Research Groups / Onc II, Bayer Pharma AG, Berlin, Germany
- Daniel R. P. Sauter
-
Current address: Sophion-Biolin Scientific, Copenhagen, Denmark
Affiliation Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark
- Alexander Ehrmann
-
Affiliation Drug Discovery, Lead Discovery / Cell Biology, Bayer Pharma AG, Berlin, Germany
- Florian Sohler
-
Affiliation Drug Discovery, Therapeutic Research Groups / Bioinformatics, Bayer Pharma AG, Leverkusen, Germany
- Andrea Hägebarth
-
Affiliation Drug Discovery, Therapeutic Research Groups / Onc II, Bayer Pharma AG, Berlin, Germany
- Ivana Novak
-
Affiliation Section for Cell Biology and Physiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark
- Sven Christian
-
* E-mail: sven.christian@bayer.com
Affiliation Drug Discovery, Therapeutic Research Groups / Onc II, Bayer Pharma AG, Berlin, Germany
Competing Interests
I. Kovalenko, L. Schoeckel, A. Glasauer, A. Ehrmann, F. Sohler, A. Haegebarth and S. Christian are employees of Bayer Pharmaceuticals. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: SC IN. Performed the experiments: IK LS AG DRPS. Analyzed the data: IK LS AG DRPS AE FS AH IN SC. Wrote the paper: IK LS AG DRPS AE FS AH IN SC. Analysed expression databases: FS.